BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
3.230
-0.130 (-3.87%)
At close: Jun 5, 2026, 4:00 PM EDT
3.210
-0.020 (-0.62%)
After-hours: Jun 5, 2026, 5:04 PM EDT
BioLineRx Revenue
BioLineRx had revenue of $477.00K in the quarter ending March 31, 2026, with 87.06% growth. This brings the company's revenue in the last twelve months to $1.40M, down -93.72% year-over-year. In the year 2025, BioLineRx had annual revenue of $1.18M, down -95.92%.
Revenue (ttm)
$1.40M
Revenue Growth
-93.72%
P/S Ratio
10.17
Revenue / Employee
$58,417
Employees
24
Market Cap
14.26M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.18M | -27.76M | -95.92% |
| Dec 31, 2024 | 28.94M | 24.14M | 502.92% |
| Dec 31, 2023 | 4.80M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBLRX News
- 8 days ago - BioLineRx (BLRX) Q1 2026 Earnings Transcript - The Motley Fool
- 11 days ago - BLRX Achieves Key Milestones in Clinical Development and Revenue Growth - GuruFocus
- 11 days ago - BioLineRx Earnings Call Transcript: Q1 2026 - Transcripts
- 11 days ago - BioLineRx Earnings release: Q1 2026 - Filings
- 11 days ago - BioLineRx reports Q1 EPS 0c vs. (0c) last year - TheFly
- 11 days ago - BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update - PRNewsWire
- 15 days ago - BioLineRx to Present GLIX1 Preclinical Data at ASCO 2026 - GuruFocus
- 16 days ago - BioLineRx and Hemispherian AS Highlight New Data on GLIX1 at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting - PRNewsWire